Bioequivalence of Flurbiprofen Lozenge vs Strepfen
Status:
Completed
Trial end date:
2018-07-15
Target enrollment:
Participant gender:
Summary
The present study has been designed to compare flurbiprofen pharmacokinetic profile after
administration of flurbiprofen 8.75 mg lozenges, marketed by ACRAF, S.p.A., Italy (test
product), and the marketed Strepfen 8.75 mg honey and lemon lozenges reference product.
(Reckitt Benckiser Portugal SA).